WAYNE, Pa., Aug. 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 21, 2009, it received a letter from Nasdaq stating that since it had not, as of the date of the letter, filed its 10-Q for the quarterly period ended June 30, 2009, it was then no longer in compliance with the rules for continued listing according to Listing Rule 5250(c)(1).
Encorium filed its Form 10-Q for the quarterly period ended June 30, 2009 on August 21, 2009. As a result, the Company received notice on August 26, 2009 from Nasdaq that it is currently in compliance with Listing Rule 5250(c)(1).
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its ap
|SOURCE Encorium Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved